Investor Ideas #Potcasts 548, #Cannabis News and #Stocks on the Move; (CSE: $CURA.C) (OTCQX: $CURLF), (CSE: $HOLL.C) (OTC: $HSTRF), (CSE: $MEDI.C) and BDSA
Delta, Kelowna, BC, April 5, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/040521-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/04051CURA-HOLL-MEDI-BDSA.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) announced a new Curaleaf branding for the Company's recently acquired retail locations and the imminent opening of its 10th store in Illinois. Additionally, Curaleaf has contributed $950,000 to impact social equity with six strategic partnerships focused on education and job training in the greater Chicagoland community as part of its Corporate Social Responsibility Rooted in Good initiative, and per the Illinois Social Equity provision in adult use regulations.
Curaleaf successfully closed its acquisition of Grassroots on July 23, 2020 and has obtained final regulatory approval from the state of Illinois for the transfer of nine Greenhouse and Windy City Cannabis retail licenses. In accordance with state guidelines, Curaleaf has begun rebranding of Windy City Cannabis retail locations in Worth, Justice, and on Weed Street in Chicago in addition to Greenhouse dispensaries located in Deerfield, Mokena, Skokie, Northbrook, Melrose and Morris.
At the nine rebranded Illinois retail locations, Curaleaf's signature teal logo will be prominently displayed and as part of the new interior design, will feature hyper-local cityscape murals that capture each store's unique location, further enhancing the experience and connection to the community. The staff at each retail location will remain committed to delivering unparalleled service and creating an inclusive experience that encourages cannabis exploration and education with a personalized approach.
Later this month, Curaleaf will be hosting a Grand Opening for its brand new 4,700 square foot Westmont store, located at 11 East Ogden Avenue in Westmont, Illinois, its 10th retail location in the state and its 103rd nationwide. In addition to a ribbon cutting event to mark the occasion, all customers will receive 15% off on purchases made on their first visit to any of the new Curaleaf stores. All rebranded stores will also host a "Curaleaf Day" on April 8 with special offers, giveaways and offerings from local restaurants.
"We are pleased to bring the Curaleaf brand to the greater Chicago area," said Joe Bayern, Curaleaf Chief Executive Officer. "The rebranding of these locations directly aligns with our strategy of building strong, national brands that deliver high-quality products backed by science to meet the needs of our patients and customers. We are also extremely proud to be active partners within these local communities and we look forward to building collaborative relationships and investing in long term opportunities with them."
This follows on the heels of Curaleef’s recent launch of Select Squeeze, a fast-acting THC-infused beverage enhancer featuring Nano-emulsification technology. The debut of Select Squeeze marked a significant milestone as one of the cannabis industry's widest national product launches. Select Squeeze was among the first cannabis products with mass availability as it became accessible to a total addressable population of 94 million adults age 21+.
As part of its "Rooted in Good" Corporate Social Responsibility platform, Curaleaf has contributed a total of $950,000 to six strategic partners in greater Chicagoland to create opportunities and sustainable impact within the cannabis industry.
Olive-Harvey College and an additional North Chicagoland community college have been selected to build programs that educate, mentor and provide internships and career opportunities within cannabis. Additionally, Curaleaf is partnering with three organizations, Cara Chicago, Growing Home and Greater West Town Community Development Project, which focus on job training to create economic opportunity and alleviate relational poverty. The Company also contributed to the Illinois Cannabis Business Development Fund, which provides technical assistance and training to support prospective entrepreneurs in applying for cannabis business establishment licenses.
Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) has partnered with one of California's leading distributors, Nabis, as demand for Hollister products continues to build. The new exclusive partnership will help streamline sales, grow retail opportunities and reduce wholesale delivery times on all orders.
Nabis supports California's cannabis market with its wholesale distribution services. Supplying more than 99% of California's dispensaries with a diverse selection of innovative products, Nabis works directly with brands to ensure timely fulfillment, and provides actionable sales data and insights to help brands scale and grow.
The partnership comes at a time when Hollister's portfolio of products continues to gain brand awareness. HashBone, a hash-infused pre-roll, is one of the company's signature products in California, and Hollister recently acquired one of Arizona's leading concentrate brands, Venom Extracts, which is coming soon to the California market. This month, Hollister will introduce Easyriders pre-rolls in a collectible tin as the first products from its collaboration with the iconic motorcycle lifestyle magazine. Hollister also has product collaborations with Tommy Chong and the veterans-aligned medicinal brand Tactical Relief.
"We are excited to be partnered with Nabis for our last mile fulfillment. Nabis has built a best-in-class last-mile fulfillment business that will help Hollister's brands reach more California dispensaries with reduced lead times," says Carl Saling, the Co-Founder, CEO and Director of Hollister Biosciences.
"While Nabis works with a wide range of cannabis brands, we always have our eye on companies with well established and diverse brand portfolios as potential partners," said Jun S. Lee, President of Nabis. "Hollister Cannabis Co. joining our family of Nabis-distributed brands is a great partnership for all parties. We look forward to distributing Hollister's high-profile, top-quality products to dispensaries across California."
Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) announced that in its pursuit to establish an investment portfolio of leading ketamine treatment centers for depression and chronic neuropathic pain, the Company has acquired the rights to a letter of intent providing for the acquisition of all of the issued and outstanding shares of NY Ketamine Medical Practice PLLC, a leading mental health and pain clinic based in New York, New York.
NY Ketamine Infusions was founded in 2012 by Dr. Glen Z. Brooks who was among the first physicians in the United States using this innovative treatment to successfully care for patients suffering from treatment-resistant depression, PTSD, mood disorders and chronic neuropathic pain. Building on over 2 decades of clinical research at major institutions like Yale University and the National Institute of Mental Health (NIMH), Dr. Brooks was at the forefront of introducing this innovative treatment to patients in need. Dr. Brooks is a board-certified anesthesiologist having completed his training at Harvard’s Brigham and Women’s Hospital and has taught at Yale University School of Medicine. As of 2021, Dr. Brooks has treated over 4,000 patients with over 50,000 ketamine infusions in his New York City office alone, representing the largest single office clinical experience in the world. His internationally renowned expertise in the field of ketamine therapy and his reputation for personal patient involvement has attracted clients from North and South America, Europe, Asia and the Middle East.
Unlike other depression medications that can take weeks or months to take effect, relief from ketamine infusions can often be experienced by patients within hours, making it especially useful for suicidal ideation. Low doses of ketamine are generally administered through a series of six infusions over a two-week period, often followed by ongoing maintenance sessions on an “as needed” basis. In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.
Based on the success of its New York City clinic, NY Ketamine Infusions has opened an additional clinic in Long Island, NY (Melville). Dr. Brooks also continues to act as a consultant for privately owned practices in Albany, NY and Madrid, Spain. He has been interviewed and quoted in numerous publications including The New York Times and was featured in Bloomberg Businessweek.1
Pursuant to the terms of the Letter of Intent, Myconic would acquire NY Ketamine Infusions in exchange for approximately USD $10,000,000, payable in cash and common shares, along with an additional number of common shares pursuant to achieving certain milestone events. The purchase price will be payable in three tranches collectively equal to USD $5,000,000 in cash and USD $5,000,000 in common shares over an 18-month period commencing upon the Company completing a financing of at least USD $10,000,000.
The shares issued at each tranche will be subject to an 18-month lock-up period, 25% of which will be released 4 months and 1 day from the respective share payment date; 37.5% of which will be released 12 months from the share payment date; and 37.5% of which will be released 18 months from the share payment date.
The common shares will be issued at a price per share equal to the volume weighted average trading price (VWAP) of the Company’s shares on the CSE for the 30-day period preceding the issuance, subject to the policies of the CSE and applicable securities laws. All securities issued pursuant to the acquisition shall be subject to a four month and one day hold period.
The completion of the acquisition is subject to a number of conditions which include but are not limited to the execution of the share purchase agreement and respective employment agreement(s), applicable lease agreements, any municipal, state, or federal licenses, copies of patents, trademarks, or intellectual property applications, completion of satisfactory due diligence, the delivery and satisfactory review of the financial statements of NY Ketamine Infusions, and the approval of the transaction by the boards of directors of each of Myconic and NY Ketamine Infusions.
BDSA, the leader in data, market intelligence and strategic guidance to the cannabis industry, announced today the availability of its new Basket Analytics solution, the most in-depth solution of its kind in the cannabis industry. BDSA Basket Analytics is now available on BDSA’s GreenEdge™ platform.
Retailers can maximize basket sizes and in-store experience via unique and strategic store layouts and planograms, positioning products most likely to be purchased together on shelves to encourage cross-sell and upsell opportunities. Further, retailers can unpack untapped promotional programs, educate their budtenders to increase basket size, and generate more consumer trips to the stores and higher basket sizes when in the store.
Manufacturers and brands can build strong retailer sales stories and relationships with quantitative proof of their brand’s value to a store. Further, they can drive successful innovation, better manage product portfolios, and create relevant and impactful marketing campaigns and promotions.
BDSA can now put specifics around how cross-brand and cross-category consumption translates to volume. Baskets containing concentrates in Colorado, for example, are among the biggest in dollar size. While concentrates tend to have a higher retail price, 20 percent of the time these shoppers are also buying flower and 14 percent of the time they are also buying edibles.
“Retailers are intently focused on increasing basket sizes and manufacturers must create and expand penetration within stores. Our new Basket Analytics solution with insights down to the brand level enables all cannabis industry participants to be more successful,” said Micah Tapman, CEO of BDSA. “More and better data enables manufacturers and retailers to make better informed decisions that lead to increased revenue, more effective promotions and enhanced market share. ”
BDSA solutions enable product development and innovation, sales and marketing activities, revenue optimization and investment decisions. Enhanced attribute coding and advanced forecasting algorithms combine to make BDSA’s market insights invaluable tools to review product attributes, velocity and distribution, and more.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Or www.potcasts.ca
